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Abstract
Background: Immune specific genes as well as genes regulating the formation of skin barrier are major determinants for
eczema manifestation. There is a debate as to whether allergic sensitization and filaggrin gene (FLG) variants lead to eczema
or FLG variants and eczema increase the risk of allergic sensitization. To investigate the time-order between eczema and
allergic sensitization with respect to FLG variants, data from a large prospective study covering infancy to late adolescence
were analyzed.
Methodology/Principal Findings: Repeated measurements of eczema and allergic sensitization (documented by skin prick
tests) at ages 1, 2, 4, 10, and 18 years were ascertained in the Isle of Wight birth cohort (n=1,456). Three transition periods
were analyzed: age 1-or-2 to 4, 4 to 10, and 10 to 18 years. FLG variants were genotyped in 1,150 participants. Over the three
transition periods, in temporal sequence analyses of initially eczema-free participants, the combined effect of FLG variants
and allergic sensitization showed a 2.92-fold (95% CI: 1.47–5.77) increased risk ratio (RR) of eczema in subsequent
examinations. This overall risk was more pronounced at a younger age (transition period 1-or-2 to 4, RR=6.47, 95% CI: 1.96–
21.33). In contrast, FLG variants in combination with eczema showed a weaker, but significant, risk ratio for subsequent
allergic sensitization only up to 10 years of age.
Conclusions/Significance: Taking the time order into account, this prospective study demonstrates for the first time, that a
combination of FLG variants and allergic sensitization increased the risk of eczema in subsequent years. Also FLG variants
interacted with eczema and increased the risk of subsequent allergic sensitization, which, was limited to the younger age.
Hence, early restoration of defective skin barrier could prevent allergic sensitization and subsequently reduce the risk of
eczema development.
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Introduction
The prevalence of common allergic disorders including eczema
has increased in recent decades among children in westernized
societies [1]. Eczema is a common chronic inflammatory skin
disorder characterized by relapsing-remitting combination of skin
dryness, pruritus, and rash starting in childhood and often
persisting into adulthood [1,2]. Allergic sensitization, character-
ized by increased immunoglobulin-E (IgE) antibodies in response
to specific allergens, has been linked to the increased risk of allergic
disorders and is believed to account for 30% to 40% of cases of
eczema, asthma, and allergic rhinitis [3,4]. In past decades, most
of the clinical etiology of eczema was attributed to genetic
predisposition to sensitization, thus relating eczema to immune
specific genes. However, the recently recognized role of a
dysfunctional skin barrier in the pathogenesis of eczema suggests
that a functional skin barrier could prevent the development of
allergic sensitization and consequently eczema [5].
One important gene involved in the formation of a normal skin
barrier is filaggrin (FLG). This gene encodes filament-aggregating
protein, which serves as a primary shield against increased
transepidermal water loss and entry of microbes, allergens, and
irritants [5,6]. The FLG gene is situated within the epidermal
differentiation complex on chromosome 1q21. Null (Loss-of-
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skin barrier and are strong predisposing factors in the development
of eczema [7]. In European populations, R501X and 2282del4 are
the most prevalent FLG variants; their association with eczema has
been replicated in several investigations, summarized in meta-
analysis [8]. Three other less common FLG variants (3702delG,
R2447X, S3247X) have also been associated with eczema
[9,10,11]. It is estimated that about 10% of European populations
carry at least one of the FLG variants [12]. Several studies have
shown that FLG variants are major risk factors for eczema in
general as well as for the subgroups of atopic and non-atopic
eczema [13,14,15]. In addition, a meta-analysis study summarized
findings of several investigations that FLG variants also increase
the risk for allergic sensitization [16].
A complex interplay between genetic, environmental, and
immunological factors is considered to contribute to the
pathogenesis of eczema [17]. However, the time-order of the
associations between allergic sensitization and eczema is highly
disputed in the literature [18] without consensus on which comes
first [19]. To our knowledge, analyses of longitudinal studies
investigating the temporal sequence of the occurrence of allergic
sensitization and eczema while accounting for the effect of FLG
variants are lacking. One position is that allergic sensitization
interacts with FLG variants leading to increased risk of eczema.
The other position is that eczema interacts with FLG variants
leading to higher risk of allergic sensitization [19]. This dispute is
more than an academic discourse, since prophylaxis can either
focus on avoiding allergic sensitization or preventing eczema. To
solve this dispute, longitudinal studies are needed that can address
the critical time order. Therefore, we assessed the interplay of FLG
variants, allergic sensitization, and eczema in a longitudinal study.
The determination of FLG variants and repeated assessments of
eczema and allergic sensitization at ages 1, 2, 4, 10 and 18 years in
the Isle of Wight birth cohort facilitate the investigation of the
combined effects. First, we investigated the individual and
combined effects of allergic sensitization and FLG variants on
the occurrence of eczema in a concurrent model (all manifestations
were detected at the same age). Second, to elucidate the temporal
sequence of events we tested two hypotheses: (i) the combined
effect of eczema and FLG variants increases the risk of subsequent
allergic sensitization and (ii) the combined effect of allergic
sensitization and FLG variants increases the risk of subsequent
eczema.
Methods
The Isle of Wight birth cohort
A whole population birth cohort was established on the Isle of
Wight, UK, in 1989 to prospectively study the natural history of
allergies from birth to 18 years of age. The island is close to the
British mainland, semi-rural, without heavy industry. Both the Isle
of Wight and the study populations are 99% Caucasian. Ethics
approvals were obtained from the Isle of Wight Local Research
Ethics Committee (now named the National Research Ethics
Service, NRES Committee South Central – Southampton B) at
recruitment and for the 1, 2, 4, 10 and 18 years follow-up (06/
Q1701/34). Of the 1,536 children born between January 1, 1989,
and February 28, 1990, written informed consent was obtained
from parents to enrol 1,456 newborns. Children were followed up
at the ages of 1 (n=1,167), 2 (n=1,174), 4 (n=1,218), 10
(n=1,373), and 18 years (n=1,313). Detailed questionnaires were
completed for each child at each follow-up. When a visit was not
possible, a telephone questionnaire was completed or a postal
questionnaire sent for completion and return.
Phenotypes
In all assessments of the Isle of Wight birth cohort, eczema was
defined as chronic or chronically relapsing, itchy dermatitis lasting
more than 6 weeks with characteristic morphology and distribu-
tion [20], following Hanifin and Rajka criteria [21]. Since the 1-
year and 2-year follow-up data on eczema were collected in a
relatively small time window, we combined them for analytic
purposes (reported as 1-or-2 years).
To determine allergic sensitization status, skin prick testing
(SPT) at ages 1 and 2 years was performed on children with any
symptoms of eczema, asthma, or rhinitis. We combined SPT
results for ages 1 and 2 years, since they occurred within a short
time period and will henceforth refer to this as SPT at 1-or-2 years.
At 4, 10 and 18 years, regardless of symptoms, SPT was performed
on most children attending the research center to a standard
battery of common allergens (ALK-Albello, Horsholm, Denmark).
Inhalant allergens tested were house dust mite, cat, dog, Alternaria
alternata, Cladosporium herbarium, grass pollen mix, and tree pollen
mix. Food allergens tested were cows’ milk, soya, hens’ egg, peanut
and cod. Positive and negative controls were included. Allergic
sensitisation was defined by having a SPT to at least one allergen
test with mean wheal diameter of 3 mm greater than the negative
control. Since allergic sensitization is a dynamic rather than a
completely stable phenotype, we used the concurrent status and
thus allowed the risk to change over time. In this manuscript we
use the terms allergic sensitization and positive SPT interchange-
ably.
FLG genotyping
We approached the participants in 1999 and ask them to
provide written informed consent to genetic analyses, when blood
samples were collected in the vast majority of children (n=907). In
2006/2007, DNA samples were collected from an additional 304
children who did not provide the samples in 1999. DNA was
extracted from blood or saliva samples from cohort subjects
(n=1,211). Five variants in the FLG gene that result in loss of
function and are reported to be common in populations of
European ancestry were selected for genotyping. DNA samples
were interrogated using GoldenGate Genotyping Assays (Illumina,
Inc, SanDiego, CA) on the BeadXpressVeracode platform
(Illumina, Inc, SanDiego, CA) per Illumina’s protocol. In brief,
samples were fragmented and hybridized to the pool of allele-
specific primer sets. Following an extension/ligation reaction the
samples were then hybridized to the Veracode bead pool and
processed on the BeadXpress reader. Data were analyzed using
the genotyping module of the GenomeStudio Software package
(Illumina, Inc, SanDiego, CA). DNA from each subject plus 37
replicate samples were analyzed for a total of 1,248 samples. The
quality threshold for allele determination was set at a GenCall
score .0.25 (scores #0.25 were ‘‘no calls’’) with n=1,227 samples
(98.3%) retained for further analysis. Analysis of each locus
included reclustering of genotyping data using our project data to
define genotype cluster positions with additional manual recluster-
ing to maximize both cluster separation and the 50th percentile of
the distribution of the GenCall scores across all genotypes (50%
GC score). Children were classified as having FLG loss-of-function
defect if they carry the minor allele for at least one of the following
FLG null variants: R501X, 2282del, or S3247X.
Statistical analysis
The study represents a dynamic cohort; some children did not
participate in one assessment but re-joined the next. For each
follow-up, the 12-month (24-month for 1-or-2 years) period
prevalence of eczema was stratified by allergic sensitization and
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divided by the number of children in the respective stratum.
Since period prevalence and transitions of eczema and allergic
sensitizations are not rare events (.10%), odds ratios for
explanatory variables are likely to overestimate risk ratios [22].
To estimate risk ratios, we applied log-binomial regression using
log link function describing the distribution of a binary variable
(i.e. dichotomous outcomes). In this type of regression, the log-
linear function describes the association between the mean
number of ‘‘successes’’ in the binomial distribution on a log-scale
and the explanatory variables. Thus, this approach enabled us to
directly estimate risk ratios, which is the exponential of the
estimated coefficients in the log-linear function. To assess long-
term development in individual children, we had to consider that
repeated measurements within one child represent correlated
observations. The within-child effect was taken into consideration
by employing a covariance matrix solved through an iterative
estimating process based on a working correlation matrix. This is
the idea of the generalized estimating equation (GEE) approach
for estimating the parameters [23]. The appropriate working
correlation matrix was determined by using the Akaike informa-
tion criterion. Applying GEE analysis using an autoregressive
working correlation matrix to take the within-child effect into
account, we estimated marginal probabilities for the risk factors
and their interaction using the GENMOD procedure in SAS 9.2
(SAS, Gary, NC, USA). For all GEE models we included age at
follow-up as categorical variables (1-or-2, 4, 10, and 18 years) and
gender as potential confounders. In this manuscript we use the
terms repeated measurement analysis and longitudinal analysis
interchangeably. A p-value,0.05 was taken to indicate statistical
significance.
First for descriptive purposes, we analyzed concurrent associ-
ations between eczema and FLG variants, eczema and SPT, and
FLG variants and SPT. Focusing on the overall cohort we
calculated risk ratios (RR) using log-binomial regression. Within
this approach, we then restricted the cohort to children with a
negative SPT and estimated the association between eczema and
FLG variants to determine the effect of FLG variants in the absence
of allergic sensitization [24]. In contrast, to determine the effect of
allergic sensitization in the absence of FLG variants, we focused on
the cohort of children without FLG variants and evaluated that
association between eczema and SPT. Then, to determine the
combined effect of both risk factors, we compared the risk of
eczema in children who have both risk factors (FLG variants and
positive SPT) to the risk of children who have neither (no FLG
variants and negative SPT). We also applied an alternate approach
using the whole sample and treating FLG variants and allergic
sensitization as main effects and estimated the combined effect
through log-binomial model {RR=exp(b16SPT+b26FLG var-
iants+b36[SPT6FLG variants])} controlling for age and gender of
the child. The interaction term (b36[SPT6FLG variants]) was
used to estimate the additional effect of two co-occurring risk
factors on the health outcome above and beyond their individual
effects. The term ‘‘combined effect’’ was used to describe the joint
impact of two individual risk factors plus their interaction on the
occurrence of the outcome. To estimate concurrent age-specific
effects, we analyzed each examination separately. To evaluate
whether there is an overall concurrent effect covering all ages, we
used repeated measurements analyses.
To address temporality and to decipher whether allergic
sensitization leads to eczema or vice versa, while accounting for
the FLG variants effect, we structured the analysis into three
transition periods (Figure 1). We have three transitions (1-or-2 to 4,
4 to 10, and 10 to 18 years) between four follow-ups (ages 1-or-2,
4, 10, and 18 years). For each transition period, at baseline
children were without the outcome (allergic sensitization or
eczema, respectively) but had either allergic sensitization or
eczema (alternate risk factors). The value of the risk factors could
change for each transition (time-dependent covariate), since
eczema and SPT were conducted at each examination. This
setting provides three repeated transition periods. In each we
assessed the interaction between the risk factors (time-dependent)
and FLG variants (time-independent) using log-binomial models.
To address the overall effect of all three transition periods, we
applied repeated measurements analyses. Hence, the alternate
models were: 1) eczema model: FLG variants 6preceding allergic
sensitization R eczema; and 2) allergic sensitization model: FLG
variants 6preceding eczema R allergic sensitization.
Results
A total of 1,377, 1,214, 1,359, and 1,307 children had available
information on eczema diagnosis at ages 1-or-2, 4, 10, and 18
years, respectively. Skin prick tests (SPTs) were performed at ages
1-or-2 (n=515, symptomatic children), 4 (n=982), 10 (n=1,036),
and 18 (n=853) years. Genotype information on the FLG variants
was available for 1,150 children. No significant group differences
were detected between the total cohort and the genotyped children
(Table 1).
FLG variants
Participants were genotyped for FLG variants R501X,
2282del4, S3247X, 3702delG, and R2447X. The polymorphic
FLG variants were in Hardy-Weinberg equilibrium. Variants
3702delG and R2447X were not informative in our population
due to minor allele frequencies ,0.1% (Table S1). Therefore, FLG
loss-of-function status was determined using R501X, 2282del4,
and S3247X variants. Minor allele frequencies of R501X,
2282del4 and S3247X were 2.0%, 2.3% and 0.8%, respectively.
The proportion of carriers (heterozygous) of FLG variants R501X,
2282del4 and S3247X were 4.1%, 4.6% and 1.6%, respectively,
resulting in a combined carrier frequency of 10.3%. No individuals
were homozygous for the minor allele of any FLG variants. One
person had a compound heterozygous genotype for R501X and
2282del4, and this person was analyzed with the heterozygotes.
Effect of FLG variants and allergic sensitization on
eczema
The combined genotype of FLG variants was strongly associated
with eczema at all time points except at 10 years of age (Table 2).
This finding is further supported by repeated measurement
analysis (age 1-or-2 to 18 years), which showed an overall effect
of FLG variants on eczema ([Risk Ratio] RR=1.56; 95% CI:
1.17–2.08). Likewise, allergic sensitization was associated with
eczema at 1-or-2, 4, 10, and 18 years of age, with the strongest
association observed at age 4 years (RR=3.05; 95% CI: 2.21–4.2;
Table 2).
Effect of FLG variants on allergic sensitization
Association analyses between FLG variants and allergic
sensitization were conducted at 1-or-2, 4, 10, and 18 years of
age, and to determine the overall association a repeated
measurement approach was applied. FLG variants increased the
risk of allergic sensitization at age 1-or-2 years (RR=1.57; 95%
CI: 1.02–2.4; Table S2) and at age 10 years (RR=1.53; 95% CI:
1.18–1.99; Table S2). At other ages (4 and 18 years) and in the
longitudinal analysis the associations were weaker.
Filaggrin, Allergic Sensitization, and Eczema
PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e32721Single and combined associations of FLG variants and
allergic sensitization with eczema
To examine the individual and combined effect of FLG variants
and allergic sensitization on the concurrent risk of eczema, we
used stratified analyses. Associations between FLG variants and
eczema were conducted among a sub-group of children who tested
negative in SPT assessments. This stratification allowed us to
determine the effect of FLG variants on the development of
eczema independent of allergic sensitization. FLG variants did not
increase the risk of eczema in the sub-group of non-allergic
children at any age or in the longitudinal analysis (RR=1.12; 95%
CI: 0.77–1.62; Table 3). Next, to determine the effect of allergic
sensitization in the absence of FLG variants, we evaluated the
association between positive SPT and concurrent eczema among
children who do not carry FLG variants. At 1-or-2, 4, and 10 years
(not at 18 years) of age a positive SPT increased risk of eczema
(longitudinal analysis, RR=1.48; 95% CI: 1.22–1.8) among
children without FLG variants. Then we assessed the combined
effect of FLG variants and allergic sensitization by comparing the
risk of eczema in children with both FLG variants and positive SPT
to the risk of eczema among children without FLG variants and
who had a negative SPT. The combined effect of FLG variants and
allergic sensitization was significant at all ages (repeated measure-
ment analysis: RR=2.82; 95% CI: 2.15–3.69) with a maximum
effect at 4 years of age (RR=8.17; 95% CI: 5.55–12.02; Table 3).
Finally, alternative to stratification, we applied a log-binomial
regression model to estimate the interaction between FLG variants
and allergic sensitization using repeated measurements. This
approach, controlling for the main effect of FLG variants and SPT,
showed that FLG variants and positive SPT have an increased
combined effect on the concurrent risk of eczema (RR=2.51; 95%
CI: 1.86–3.38; Table 3). Thus, stratification and modelling
approaches yielded comparable results.
Association analyses accounting for temporal sequence
of events
To address temporality of allergic sensitization and eczema we
analyzed three transition periods (1-or-2 to 4, 4 to 10, and 10 to 18
years) between four follow-ups (ages 1-or-2, 4, 10, and 18). At the
baseline of the transition period, children were without the
outcome but had developed eczema in the next exam: 6.2%,
9.4%, and 6.7%, respectively, between 1-or-2 and 4 years, 4 and
10 years, and 10 and 18 years, or had developed allergic
sensitization: 14.2%, 14.8%, and 23.1%, respectively (Table 4).
The combined effect of allergic sensitization in the preceding exam
and FLG variants on the development of eczema (eczema model)
showed a 2.92-fold increased risk (95% CI: 1.47–5.77) in the
longitudinal analysis. Alternatively, we tested whether the
combined effect of eczema in the preceding exam and FLG
variants affected the development of positive SPT (allergic
sensitization model), but did not find a significant association in
the repeated measurements analysis.
Figure 1. Graphical presentation of temporal (time-order) analyses. ‘‘+ SPT’’ refers to positive skin prick test. Between four follow-ups (ages
1-or-2, 4, 10, and 18 years) three transition periods (1-or-2 to 4, 4 to 10, and 10 to 18) were analyzed. The combined effect of eczema and FLG variants
on the development of subsequent allergic sensitization (defined by positive SPT) was determined for the three transition periods separately and in
repeated measurement analysis. Similarly, the combined effect of allergic sensitization and FLG variants on the development of subsequent eczema
was determined. Dashed arrows refer to the combined effect of eczema and FLG variants on the development of + SPT. Solid arrows represent the
combined effect of + SPT and FLG variants on the development of eczema.
doi:10.1371/journal.pone.0032721.g001
Table 1. Characteristics of total cohort and subpopulation of










Male 51.2 (786/1536) 49.5 (569/1150) 0.243
Female 48.8 (750/1536) 50.5 (581/1150) 0.243
Eczema
At 1-or-2 years 14.2 (196/1377) 15.1 (162/1076) 0.421
At 4 years 11.9 (145/1214) 11.8 (119/1008) 0.926
At 10 years 13.7 (186/1359) 14.7 (164/1118) 0.346
At 18 years 12.3 (161/1307) 12.2 (132/1086) 0.884
Allergic sensitization
At 1-or-2 years
{ 20.6 (106/515) 21.9 (98/447) 0.489
At 4 years 19.6 (192/982) 20.4 (172/843) 0.557
At 10 years 26.9 (279/1036) 27.9 (266/954) 0.494
At 18 years 41.4 (353/853) 42.3 (336/794) 0.311
*Genotyped subpopulation represents the number of children with genotype
information for R501X, 2282del and S3247X FLG variants.
{Two-sided one sample binomial tests were used to determine if statistical
differences are present when comparing proportions for the genotyped
subpopulation with their respective proportions in the total cohort.
{Skin prick tests were performed on symptomatic children (i.e. children with
symptoms of eczema, asthma, or rhinitis) at age 1-or-2 years.
doi:10.1371/journal.pone.0032721.t001
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present in the analysis of the temporal sequence, we determined
the risk associated with the combined effect for each transition
separately. The combined effect of FLG variants and allergic
sensitization statistically significantly increased the risk of subse-
quent eczema for the transition periods 1-or-2 to 4 years
(RR=6.47; 95% CI: 1.96–21.33, p-value=0.002; Figure 2A)
and 10 to 18 years (RR=2.68; 95% CI: 1.04–6.9, p-
value=0.041), which was further supported by repeated measure-
ments analysis that suggested the overall effect of all transition
periods is statistically significant (Table 4). In contrast, the
combined effect of FLG variants and eczema statistically
significantly increased the risk of allergic sensitization only for
the transition periods 1-or-2 to 4 years (RR=3.5; 95% CI: 1.46–
8.39, p-value=0.005) and 4 to 10 years (RR=2.88; 95% CI:
1.05–7.95, p-value=0.041; Figure 2B). The overall effect of the
three transitions periods for this model (allergic sensitization
model) was not statistically significant (Table 4).
Discussion
Using data of a large follow-up study from infancy to age 18
years, our study explores two assertions: first, the combined
occurrence of eczema and FLG variants leads to allergic
sensitization, second, the combined effect of allergic sensitization
and FLG variants leads to eczema. We applied two explanatory
models, a concurrent and a delayed effect (time order) model
(Figure 1), and investigated both the overall effect (repeated
measurements) of eczema and allergic sensitization and period-
specific effects (ages 1-or-2, 4, 10 and 18 years). In the repeated
measurement analyses of concurrent effects, FLG variants, in the
absence of a positive SPT, did not significantly increase the risk of
the concurrent eczema (RR=1.12). In contrast, among individ-
uals without FLG variants, allergic sensitization was associated
with concurrent risk of eczema (RR=1.48). In the presence of
both FLG variants and allergic sensitization (combined effect), a
considerable increase in the risk ratio was observed (RR=2.82).
Focussing on the temporal sequence in repeated measurement
analyses, we found that among eczema-free children, a positive
SPT combined with FLG variants showed a significant interaction
(combined effect RR=2.92) on the occurrence of eczema in
subsequent follow-up examinations up to 18 years of age. In
contrast, in non-sensitized children the combined effect of eczema
and FLG variants posed no overall increased risk for subsequent
allergic sensitization, but only for the transition periods 1-or-2 to 4
years and 4 to 10 years.
Other birth cohort studies, the Copenhagen Study on Asthma
in Childhood (COPSAC), the Manchester Asthma and Allergy
Study (MAAS), the Prevention and Incidence of Asthma and Mite
Allergy (PIAMA) in the Netherland, and the Avon Longitudinal
Study of Parents and Children (ALSPAC), have ascertained FLG
variants and eczema longitudinally up to the age of 5, 8, and 11
years, respectively, with several repeated measurements [13,25,
26]. However, the temporal sequence of eczema and allergic
sensitization in interaction with FLG variants was not tested.
Nonetheless, when comparing the results of our concurrent models
with these studies, the magnitude of the associations between FLG
variants and eczema is comparable. In our cohort, at 4 years of
age FLG variants increased the risk of eczema by approximately 2-
fold (RR=1.92; 95% CI: 1.27–2.91). Similarly, results from the
COPSAC cohort study demonstrated that FLG variants increase
the risk of eczema during the first five years of life by almost the




% (n/total) WT LOF Negative Positive
Eczema at 1-or-2 14.1 (136/964) 23.2 (26/112) 29.6 (121/409) 56.6 (60/106)
RR (95% CI)
* 1.00 1.64 (1.13–2.38) 1.00 1.94 (1.55–2.42)
P-value 0.009 ,0.001
Eczema at 4 10.8 (97/902) 20.8 (22/106) 9.0 (71/788) 27.5 (53/193)
RR (95% CI)
* 1.00 1.92 (1.27–2.91) 1.00 3.05 (2.21–4.2)
P-value 0.002 ,0.001
Eczema at 10 14.1 (142/1004) 19.3 (22/114) 13.0 (98/757) 21.9 (61/279)
RR (95% CI)
* 1.00 1.37 (0.91–2.05) 1.00 1.71 (1.28–2.29)
P-value 0.129 ,0.001
Eczema at 18 11.5 (112/975) 18.0 (20/111) 9.8 (49/500) 15.9 (56/353)
RR (95% CI)
* 1.00 1.6 (1.04–2.46) 1.00 1.73 (1.21–2.48)
P-value 0.031 0.003
Repeated measurement analysis
Eczema 12.7 (487/3845) 20.3 (90/443) 13.8 (339/2454) 24.7 (230/931)
RR (95% CI)
{ 1.00 1.56 (1.17–2.08) 1.00 1.67 (1.41–1.97)
P-value 0.003 ,0.001
RR: Risk ratio; CI: Confidence interval; WT: Wild-type; LOF: Loss-of-function.
*Association adjusted for gender.
{Association adjusted for gender and age at follow-up.
{Combined genotypes of R501X, 2282del and S3247X variants; WT refers to individuals with wild-type genotypes for all three variants; LOF refers to individuals with a
minor allele for at least one of the three variants.
doi:10.1371/journal.pone.0032721.t002
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results from the PIAMA cohort study showed that FLG variants
were associated with eczema during the first eight years of life
(OR=2.0; 95% CI: 1.4–2.8) [25]. A slightly higher risk of eczema
due to FLG variants during the first 11 years of life (OR=2.46;
95% CI: 2.02–2.99) was reported by the ALSPAC cohort study
[13].
A report of the German Multicentre Allergy Study (MAS)
cohort show an interaction effect of FLG variants and food
sensitization (RR=4.07; 95% CI: 2.94–5.65) on the development
of concurrent ‘‘eczema-associated asthma’’ from birth to 13 years
of age [28]. In our study we investigated the combined effects of
FLG variants and allergic sensitization (instead of food sensitization
only) on the development of eczema (not ‘‘eczema-associated
asthma’’). Using repeated measurements from age 1-or-2 to age
18, we found that allergic sensitization interacts with FLG variants
and increase the risk of concurrent eczema (RR=2.82).
Without considering FLG variants, previous longitudinal
investigations showed inconsistent results as to whether manifes-
tation of eczema occurs before or after allergic sensitization
development [18]. A report based on Melbourne Atopy Cohort
Study (MACS, investigating the period from 6 months to 7 years
of age) suggested that allergic sensitization may precede eczema
development or eczema develops before allergic sensitization
[29]. In contrast, results from the Childhood Asthma Prevention
Study (CAPS) cohort in Sydney showed that eczema preceded
and increased the risk of subsequent allergic sensitization between
ages 18 months to 5 years [30]. Both studies did not account for
the effect of FLG variants and did not cover the period of
adolescence. When investigating the temporal sequence of events
in relation to FLG variants effect, we found that both directions
coexist. The combined effect of FLG variants and eczema leading
to later allergic sensitization was only seen in the first decade of
life. This finding speaks in favour of the model proposed by Cork
et al., suggesting that the skin barrier is less developed at younger
ages, which might explain the increased risk of allergic
sensitization associated with FLG variants and eczema only in
infants and young children [5]. For the transition period 10 to 18







children without FLG variants
Combined effect
{ of FLG variants
and allergic sensitization
% (n/total) WT LOF SPT 2 SPT + WT & SPT 2 LOF & SPT +
Eczema at 1-or-2 28.0 (87/311) 31.6 (12/38) 28.0 (87/311) 53.8 (43/80) 28.0 (87/311) 72.2 (13/18)
RR (95% CI)
" 1.00 1.13 (0.68–1.86) 1.00 1.93 (1.47–2.52) 1.00 2.67 (1.93–3.69)
P-value 0.638 ,0.001 ,0.001
Eczema at 4 8.3 (50/605) 9.0 (6/67) 8.3 (50/605) 20.6 (30/146) 8.3 (50/605) 64 (16/25)
RR (95% CI)
" 1.00 1.08 (0.48–2.43) 1.00 2.49 (1.65–3.77) 1.00 8.17 (5.55–12.02)
P-value 0.849 ,0.001 ,0.001
Eczema at 10 13.3 (84/632) 12.5 (7/56) 13.3 (84/632) 19.8 (45/227) 13.3 (84/632) 30.8 (12/39)
RR (95% CI)
" 1.00 0.94 (0.46–1.94) 1.00 1.5 (1.08–2.09) 1.00 2.52 (1.49–4.23)
P-value 0.869 0.016 ,0.001
Eczema at 18 10.1 (42/416) 7.1 (3/42) 10.1 (42/416) 13.7 (40/293) 10.1 (42/416) 25.6 (11/43)
RR (95% CI)
" 1.00 0.73 (0.24–2.24) 1.00 1.46 (0.97–2.19) 1.00 3.09 (1.78–5.37)
P-value 0.584 0.069 ,0.001
Repeated measurement analysis
Eczema 13.4 (263/1964) 13.8 (28/203) 13.4 (263/1964) 21.2 (158/746) 13.4 (263/1964) 41.6 (52/125)
RR (95% CI)
$ 1.00 1.12 (0.77–1.62) 1.00 1.48 (1.22–1.8) 1.00 2.82 (2.15–3.69)
P-value 0.571 ,0.001 ,0.001
Repeated measurement analysis (modeling approach)
Variable Coefficient RR (95% CI) P-value
FLG variants 0.08 1.09 (0.74–1.59) 0.675
Allergic sensitization 0.41 1.51 (1.24–1.84) ,0.001
Interaction term 0.43 1.53 (0.94–2.49) 0.089
Combined effect
# 0.92 2.51 (1.86–3.38) ,0.001
RR: Risk ratio; CI: Confidence interval; WT: Wild-type; LOF: Loss-of-function; SPT 2: Negative skin prick test; SPT +: Positive skin prick test.
Combined genotypes of R501X, 2282del and S3247X variants; WT refers to individuals with wild-type genotypes for all three variants; LOF refers to individuals with a
minor allele for at least one of the three variants.
*All children are non-allergic (defined by negative skin prick test at the concurrent eczema assessment).
{All children are wild type for FLG null variants.
{Children with both positive skin prick test and FLG LOF variants were compared to children with negative skin prick test and wild-type FLG.
"Association adjusted for gender.
$Association adjusted for gender and age at follow-up.
#The combined effect RR was estimated as: RR=exp(0.08+0.41+0.43).
doi:10.1371/journal.pone.0032721.t003
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(Eczema model) and allergic sensitization (Allergic sensitization model).
Eczema model
* Allergic sensitization model
{
Transition of eczema % (n/total)
{ Transition of allergic sensitization % (n/total)
{
Transition period (age in years) Transition period (age in years)
1-or-2 to 4 4 to 10 10 to 18 1-or-2 to 4 4 to 10 10 to 18
6.2 (18/292) 9.4 (69/732) 6.7 (51/761) 14.2 (44/310) 14.8 (90/607) 23.1 (118/512)
Repeated measurement analysis Repeated measurement analysis
Variable Coefficient
RR
(95% CI) P-value Variable Coefficient
RR
(95% CI) P-value
Allergic sensitization 20.36 0.7
(0.42–1.15)
0.157 Eczema 0.15 1.16
(0.84–1.61)
0.367
FLG variants 0.04 1.04
(0.57–1.89)
0.896 FLG variants 0.1 1.11
(0.72–1.7)
0.651
Interaction term 1.39 4.02
(1.49–10.85)










RR: Risk ratio; CI: Confidence interval.
*This log-binomial model tests whether allergic sensitization, FLG variants and their interaction predict the transition of eczema (change is disease status from eczema-
free to eczema in three consecutive study assessments). Also, gender and age at follow-up were included in the model as covariates.
{This log-binomial model tests whether eczema, FLG variants and their interaction predict the transition of allergic sensitization (change in status from having negative
skin prick test to positive skin prick test in three consecutive study assessments). Also, gender and age at follow-up were included in the model as covariates.
{Refers to the percent of children who were eczema-free or non-atopic at the initial assessment of the transition period and developed eczema or allergic sensitization
at the second assessment of the same transition period.
"RR of combined effect of allergic sensitization and FLG variants on development of eczema was calculated as: RR=exp(20.36+0.04+1.39).
$RR of combined effect of eczema and FLG variants on development of allergic sensitization was calculated as: RR=exp(0.15+0.1+0.31).
doi:10.1371/journal.pone.0032721.t004
Figure 2. Overall and time-specific risk ratios in the temporal (time-order) analyses. (A) Risks ratios associated with the combined effect of
FLG variants and allergic sensitization on the development of subsequent eczema for three transition periods and repeated measurements. (B) Risk
ratios associated with the combined effect of FLG variants and eczema on the development of subsequent allergic sensitization for three transition
periods and repeated measurements. ‘‘RM’’ refers to repeated measurements.
doi:10.1371/journal.pone.0032721.g002
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effect on the development of subsequent allergic sensitization.
This observation is further supported by a previous study which
showed that the majority of children carrying FLG variants
outgrow eczema by 12 years of age [13]. Hence, in the transition
from 10 to 18 years, the eczema 6FLG variants interaction may
no longer add to the risk of allergic sensitization. Overall,
compared to the combined effect of eczema and FLG variants on
allergic sensitization, the combined effect of FLG variants and
allergic sensitization leading to eczema was stronger, particularly
in early childhood, and covered the first two decades of life
(Figure 2). This novel finding suggests strongly that allergic
sensitization is not an epiphenomenon of eczema or its sequel,
but a risk factor for subsequent eczema.
The longitudinal design of the Isle of Wight birth cohort study
that covered the first 18 years of life is a major strength of our
study. Throughout all assessments, the proportion of participa-
tion remained high, which ruled-out a major bias due to loss-to-
follow up. Moreover, SPTs were repeatedly performed, thus
allowing us to treat allergic sensitization as a time-dependant
covariate. The prevalence of eczema and allergic sensitization did
not differ between the total cohort and the sample that had
available FLG variants genotypes (Table 1). Thus, there is no
indication of a selection bias. Misclassification of eczema cases is
minimal since a high proportion of subjects showed typical
manifestation of eczema in usual locations (antecubital or
popliteal fossae, ankles, face or neck for 97% at 1 year, 91% at
2 years, 75% at 4 years, 86% at 10 years and 76% at 18 years)
[31]. In addition, the prevalence of eczema in our cohort (13.7%
at age 10 years and 12.3% at age 18 years) is comparable to
results from the International Study of Asthma and Allergies in
Childhood aged 13–14 years in the United Kingdom (UK)
(14.7% phase one and 10.6% phase three) and other studies
conducted in the UK [32,33,34]. The proportion of FLG variants
carriers in our study population (10.3%) is similar to the
estimated heterozygous carries (10%) for individuals of European
ancestry [12]. In line with previous studies, individuals homozy-
gous for the minor allele of FLG variants were rarely identified
due to the low minor allele frequencies of these variants
[13,25,35].
A limitation of this study is that we have information on SPTs
for the exams at age 1 and 2 years only for symptomatic children.
However, there is no suspicion that the inclusion of the SPT at age
1 and 2 resulted in a selection bias: First, in both the eczema and
the control children at age 1-or-2 the proportion of positive SPT is
not higher than at age 4 when all available children were skin prick
tested (21.9 vs. 20.4, Table 1). Second, there is no increased risk
ratio of allergic sensitization at age 1-or-2 for eczema compare to
other ages (Table 2). Statistical power could be another potential
limitation due to the low sample sizes in some of the analyzed
subgroups. However, statistical significance was demonstrated for
most of the clinically important effects (i.e. associations with RR
considerably higher than the null). Therefore, we believe that our
study was not underpowered to detect statistically significant and
clinically important associations.
Our results suggest that a defective skin barrier and altered
immune responses work synergistically to increase susceptibility
to eczema, a concept recently proposed by Biagini Myers et al.
[36]. Null variants in FLG result in the formation of a disrupted
skin barrier that predisposes to higher risk of eczema due to
higher penetration of environmental factors (outside-inside
barrier) and excessive water loss (inside-outside barrier) [17].
Our findings, that allergic sensitization is associated with eczema
even in the absence of FLG variants, further support the concept
that penetration of allergens leading to manifestation of eczema
may also be related to other factors that regulate the integrity of
the skin barrier. Therefore, factors regulating the immune
response as well as genes responsible for the formation of
functional skin barrier, may play a role in the pathophysiology of
eczema [37].
A recent study showed that the skin barrier is compromised
even in non-FLG variants carriers, supporting the notion that other
factors may be important for the formation of a functional skin
barrier [38]. Recent reports suggested that a single nucleotide
polymorphism within the HRNR (hornerin) gene, located 78 kb
away from FLG, conferred susceptibility to eczema [39,40]. Hence
comprehensive tests of genetic variants in the epidermal
differentiation complex will improve the sensitivity of identifying
susceptible children. Improved knowledge of skin susceptibility
factors would then enhance randomization of susceptible groups to
test treatment effects of possible skin treatments.
In conclusion, no prior study has investigated the long-term
development of eczema and allergic sensitization with respect
to interactions with FLG variants. The results of our
longitudinal study covering the first 18 years of life corroborate
prior findings that a higher risk of eczema is associated with
FLG variants. For the first time, taking the time-order into
account, we estimated the risk ratio of interaction of FLG
variants with allergic sensitization and eczema on later
occurrence of eczema or allergic sensitization, respectively.
We demonstrated that both directions coexist; however, the
interaction between allergic sensitization and FLG variants on
subsequent eczema was more important: First, this interaction
was detected in both childhood and adolescence, whereas the
effect of the FLG variants 6 eczema interaction was only seen
up to the age of 10 years. Second, the interaction FLG variants
6 allergic sensitization was stronger particularly in early
childhood. The findings suggest that improvements of the skin
barrier, for example by using barrier creams or anti-inflam-
matory treatments, at an early age may reduce the risk of
eczema associated with the combination of FLG variants and
allergic sensitization.
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